In this Issue:
Continuing BRAF inhibitors beyond PD improves OS
BRAF/MEK inhibitor combination prolongs PFS. . .
. . . and improves survival in BRAF-mutant disease
Vemurafenib + cobimetinib in BRAF-mutated melanoma
Pyrexia common with dabrafenib + trametinib
Blood-based assay quantifies BRAF V600E levels
Nivolumab in untreated melanoma without BRAF mutation
Pembrolizumab active in metastatic melanoma
Which melanoma patients benefit from CTLA-4 blockade?
Risk factors for late recurrences of melanoma
Please login below to download this issue (PDF)